Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant erythropoietin.

R D Christensen1

  • 1Division of Human Development and Aging, University of Utah School of Medicine, Salt Lake City.

Pediatrics in Review
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Recombinant erythropoietin offers a potential alternative to erythrocyte transfusions for pediatric patients with anemia, particularly those with end-stage renal disease or prematurity. Further studies are needed to confirm its safety and efficacy in children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Gynecologic oncology·2024
Same author

Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Reference intervals for stool calprotectin in preterm neonates and their utility for the diagnosis of necrotizing enterocolitis.

Journal of perinatology : official journal of the California Perinatal Association·2018
Same author

ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program.

Journal of perinatology : official journal of the California Perinatal Association·2018
Same author

The immature platelet fraction: creating neonatal reference intervals and using these to categorize neonatal thrombocytopenias.

Journal of perinatology : official journal of the California Perinatal Association·2017
Same author

The iron status at birth of neonates with risk factors for developing iron deficiency: a pilot study.

Journal of perinatology : official journal of the California Perinatal Association·2016
Same journal

Hemangiomas: Beyond the Skin.

Pediatrics in review·2026
Same journal

More Than Innocent: A Continuous Murmur in an Infant.

Pediatrics in review·2026
Same journal

Genetic Testing.

Pediatrics in review·2026
Same journal

Visual Diagnosis: Term Infant With a Hemorrhagic Dermatologic Lesion.

Pediatrics in review·2026
Same journal

Long-Term Complications of Sickle Cell Disease.

Pediatrics in review·2026
Same journal

Pediatric Multisystemic Illness With Cardiac Involvement: A Diagnostic Challenge.

Pediatrics in review·2026
See all related articles

Area of Science:

  • Biotechnology
  • Hematology
  • Pediatrics

Background:

  • The cloning and expression of the human erythropoietin gene have enabled the production of recombinant erythropoietin (EPO).
  • This advancement facilitates clinical and laboratory investigations into EPO's role in health and disease.

Purpose of the Study:

  • To investigate the potential of recombinant erythropoietin as a therapeutic agent for anemia in pediatric populations.
  • To clarify the mechanisms regulating erythropoietin production.

Main Methods:

  • Cloning and expression of the human erythropoietin gene.
  • Clinical and laboratory investigations using recombinant erythropoietin.

Main Results:

  • Recombinant erythropoietin is now available for research and clinical use.

Related Experiment Videos

  • Investigations are elucidating erythropoietin regulation in various conditions.
  • Erythropoietin administration shows promise in reducing or replacing erythrocyte transfusions for specific pediatric anemia cases.

    • Conclusions:

    • Pediatric patients with anemia of end-stage renal disease and anemia of prematurity are potential beneficiaries.
    • Additional controlled studies are essential to evaluate the risks and benefits before widespread use in anemic children.